Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NY-ESO-1 peptide vaccine + Sirolimus |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NY-ESO-1 peptide vaccine | NY-ESO-1 peptide vaccine is a vaccine targeting the cancer-testis antigen, NY-ESO-1, which may stimulate a cytotoxic T-cell (CTL) response against tumor cells expressing NY-ESO-1, resulting in antitumor activity (PMID: 12488431, PMID: 17652518). | |||
Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |